NCT03946592View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat

PHASE3CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

July 2, 2020

Study Completion Date

July 2, 2020

Conditions
Submental Fat
Interventions
DRUG

Normal saline

Inject the Drug into submental fat via subcutaneous

DRUG

DWJ211

Inject the Drug into submental fat via subcutaneous

Trial Locations (1)

Unknown

Chung-ang university hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT03946592 - Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat | Biotech Hunter | Biotech Hunter